NVAX R&D to Revenue
Novavax Inc · R&D to Revenue
NVAX R&D to Revenue
Latest reported29.98%period ending
NVAX FY R&D/Revenue (3700.00% → 29.98%)
Latest values, visible window
High-resolution chart · PNG
NVAX r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 29.9801% | |
| 57.3425% | |
| 132.5532% | |
| 77.2555% | |
| 1,282.7691% | |
| 3,336.7295% | |
| 610.0204% | |
| 506.8741% | |
| 540.2714% | |
| 1,549.7883% | |
| 448.6731% | |
| 259.0919% | |
| 240.5355% | |
| 118.0513% | |
| 121.7661% | |
| 8,172.5948% | |
| 7,932.3077% | |
| 2,287.0301% | |
| 1,163.2518% | |
| 246.1883% | |
| 68.6925% | |
| 89.2131% | |
| 85.3458% | |
| 76.6478% | |
| 44.7727% | |
| 378.101% | |
| 283.3333% | |
| 485.7143% | |
| 580% | |
| 3,700% |